紫杉醇联合洛铂化疗方案对晚期初治卵巢癌术后患者早期临床疗效及毒副反应发生率的分析

摘要

目的 探讨分析紫杉醇(paclitaxel,PTX)联合洛铂(lobaplatin,LBP)或卡铂(carboplat,CBP)化疗方案在晚期初治卵巢癌术后患者的早期临床疗效及安全性.方法 2013年10月至2015年8月安丘市人民医院收治的经病理学证实的晚期卵巢癌患者60例,均为初治且接受肿瘤细胞减灭术治疗.依据术后化疗方案不同将其分为TL组与TC组,每组各30例.其中TL组采用PTX+LBP化疗方案,TC组予以PTX+CBP方案.治疗期间检测血清肿瘤抗原125(cancerantigen 125,CA 125)、肿瘤标志物人附睾蛋白4(human epididymisprotein 4,HE 4)水平,并于治疗结束后评估临床疗效及不良反应.结果 至治疗结束,TL组完全缓解(complete remission,CR)8例(26.7 %),部分缓解(partial remission,PR)15例(50.0 %),有效(RR=CR+PR)率为76.7 %(23/30);与 TC 组(73.3 %,22/30)比较差异无统计学意义(P >0.05).治疗后两组CA 125、HE 4均恢复正常水平,治疗期间TL组上述指标下降更为迅速(P<0.05);但骨髓抑制发生率TC组低于TL组(P<0.05).结论 TL与TC方案对晚期卵巢癌均有确切疗效,但TL方案起效更为迅速,且安全性更高.%Objective To investigate the early clinical efficacy and safety of paclitaxel(PTX)combined with lobaplatin(LBP) or carboplatin(CBP)in the early stage of ovarian cancer.Methods 60 patients with advanced ovarian cancer confirmed by pathology were initially treated with tumor cell reduction surgery in People's Hospital of Anqiu City from October 2013 to August 2015.According to the different postoperative chemotherapy regimen, they were divided into TL group and TC group, each with 30 cases.TL group received PTX +LBP chemotherapy regimen,TC group was given PTX +CBP program.Serum CA125 and HE4 levels were measured during treatment and clinical efficacy and adverse reactions were assessed after treatment.Results To the end of treatment,8 cases of complete remission(CR),15 cases of partial remission(PR)in the TL group,the effective rate was 76.7 %,there was no significant difference compared to the TC group(73.3%)(P>0.05).The levels of CA125 and HE4 in the two groups returned to normal level, and during the treatment period,the above indexes in the TL group decreased more rapidly(P <0.05).But the incidence of bone marrow suppression in TC group was lower than that in TL group(P<0.05).Conclusion TL and TC regimens have definite curative effect on advanced ovarian cancer,but TL group is more rapid and safe.